Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNeuren Pharmaceuticals Ltd

Neuren Pharmaceuticals Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
23.24 AUD 0.00(0%)
Last update at 2026-11-06T06:17:00Z
VOLUME
1050470
Market Cap
2946.23M
P/E
154.93

Momentum Score

…

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
22.87
Low
23.92
High
52 Week Price Range
10.92
Low
23.59
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Neuren Pharmaceuticals (ASX: NEU) is a clinical-stage biotech developing peptide therapies for neurodevelopmental disorders, notably NNZ-2566 (trofinetide) licensed to a commercial partner and NNZ-2591 advancing in clinical development. Long-term growth may be supported by royalty and milestone revenue from trofinetide, potential partnering or label expansion for NNZ-2591, and adoption in rare pediatric neurology.
Principal risks are concentration on a single royalty-bearing product and reliance on a partner for commercialization, clinical and regulatory uncertainty for NNZ-2591, limited internal resources and the potential need for additional funding, and challenges with market access.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
23.24
Dividend Yield
0.76%
Revenue TTM
69.53M
Revenue Per Share
0.54
Gross Profit TTM
20.61M
Debt / Equity
-
ROE
6.17%
Net Debt
-4.23M
ROCE
6.51%
Diluted EPS TTM
0.15

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 38.93M 182.94M 205.14M 0.18M -7.79M
Net income 30.44M 142.04M 157.08M 2.37M -7.75M
Selling general administrative - 4.70M 5.95M 3.44M 1.91M
Selling and marketing expenses - - 0.02M - -
Gross profit 64.61M 213.22M 205.17M 14.55M -
Reconciled depreciation - 0.02M 0.02M 0.01M 0.01M
Ebit 22.02M 175.55M 199.25M -1.61M -11.44M
Ebitda 22.05M 175.57M 199.26M -1.60M -11.43M
Depreciation and amortization 0.02M 0.02M 0.02M 0.01M 0.01M
Operating income 22.02M 175.55M 172.49M -1.61M -11.44M
Other operating expenses 42.61M 37.69M 59.45M 16.16M 11.44M
Interest expense - - - 0.39M 3.64M
Tax provision - 40.90M 48.06M 0.00M 0.00M
Interest income - 11.01M 5.69M 0.39M 0.40M
Net interest income - 11.01M 5.69M 0.39M 0.04M
Income tax expense 8.49M 40.90M 48.06M -2.18M -0.05M
Total revenue 64.63M 213.24M 231.93M 14.55M 0.04M
Total operating expenses 42.59M 37.67M 32.70M 16.16M 11.44M
Cost of revenue 0.02M 0.02M 26.75M - -
Total other income expense net 16.91M 7.39M 32.65M 1.79M 3.64M
Net income from continuing ops - 142.04M 157.08M 0.18M -7.79M
Net income applicable to common shares - 142.04M 157.08M 0.18M -7.79M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 342.86M 409.71M 247.97M 43.27M 40.06M
Other current assets 9.57M 4.17M 4.21M 1.98M 1.84M
Total liab 4.41M 45.80M 42.76M 1.68M 0.80M
Total stockholder equity 338.45M 363.90M 205.21M 41.59M 39.25M
Other current liab 3.46M 44.31M 42.09M 1.42M 0.56M
Common stock 134.94M 165.27M 173.13M 167.74M 167.58M
Capital stock - - 173.13M 167.74M 167.58M
Retained earnings 210.87M 180.43M 38.39M -118.69M -118.88M
Other assets - - 0.00M - -
Cash 4.23M 3.15M 17.09M 40.18M 36.78M
Cash and equivalents - - - 37.88M 29.87M
Total current liabilities 4.34M 45.76M 42.76M 1.68M 0.80M
Net debt -4.23M -3.15M -17.09M -40.18M -36.78M
Short term debt - - - 0.00M 0.00M
Other stockholder equity - 0.00M - -10.68M -9.45M
Property plant equipment - - - 0.02M 0.01M
Total current assets 332.23M 399.33M 247.16M 43.25M 40.04M
Net tangible assets - - - 41.59M 39.25M
Short term investments 291.89M 219.09M 211.44M - -
Net receivables 26.54M 172.91M 14.41M 1.09M 1.42M
Accounts payable 0.88M 1.45M 0.68M 0.26M 0.24M
Accumulated other comprehensive income -7.36M 18.20M -6.31M -7.46M -9.45M
Non currrent assets other - 10.35M -0.00M - -
Non current assets total 10.63M 10.38M 0.81M 0.02M 0.01M
Long term debt total - - - 0.00M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 4.13M -211.49M -0.02M -0.01M
Change to liabilities - - - 0.34M -0.11M
Total cashflows from investing activities -88.01M 4.13M -211.49M -0.02M -0.01M
Total cash from financing activities -33.22M -8.78M 3.62M -0.00M 22.18M
Net income 30.44M 142.04M 157.08M 2.37M -7.79M
Change in cash 1.07M -13.94M -23.09M 3.40M 12.60M
Begin period cash flow 3.15M 17.09M 40.18M 36.78M 24.19M
End period cash flow 4.23M 3.15M 17.09M 40.18M 36.78M
Total cash from operating activities 125.42M -11.27M 184.93M 2.38M -9.97M
Issuance of capital stock - 1.66M 3.64M - 23.28M
Depreciation 0.02M 0.02M 0.02M 0.01M 0.01M
Other cashflows from investing activities - 4.14M -211.44M - -
Change to account receivables 154.59M -157.11M -15.55M 0.19M -2.51M
Sale purchase of stock -39.57M -10.43M -0.02M -0.00M -1.11M
Other cashflows from financing activities - 1.65M -211.49M -0.02M -0.01M
Change to netincome - - - 2.87M 0.44M
Capital expenditures 0.04M 0.01M 0.04M 0.02M 0.01M
Change in working capital 96.02M -157.59M 23.24M -1.23M 0.82M
Stock based compensation - 1.23M 2.93M - -
Other non cash items -1.06M 4.27M 7.52M -2.38M 7.79M
Free cash flow 125.39M -11.28M 184.88M 2.36M -9.98M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 31.95 160.40
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 3.85 47.29
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 18.28 -9.86
PYC
PYC Therapeutics Ltd		 -0.05
2.59%		 1.88 - 12.00 73.11 2.63 25.02 -8.41

Profile*

Neuren Pharmaceuticals Ltd

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.

117 Camberwell Road, Hawthorn East, VIC, Australia, 3123

61 3 9092 0480

https://www.neurenpharma.com

Name Title Year Born
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons) CEO, MD & Director NA
Ms. Lauren Frazer C.A. CFO & Company Sec. NA
Mr. Lawrence Glass Chief Science Officer NA
Mr. Gerry Zhao VP of Corp. Devel. NA
Dr. Liza A. Squires M.D. Chief Medical Officer NA
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. CEO, MD & Executive Director NA
Ms. Lauren Frazer C.A. CFO & Company Secretary NA
Mr. Lawrence Glass BA (Biology) Chief Science Officer NA
Mr. Gerry Zhao Vice President of Corporate Development NA
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. CEO, MD & Executive Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…